Aeon Biopharma Inc (AEON)

$0.77 +0.08 (11.58%)
Market Cap 7.80M
Revenue (ttm) 0.00
Net Income (ttm) 42.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 115,700
Avg Vol 161,140
Day's Range N/A - N/A
Shares Out 11.31M
Stochastic %K 82%
Beta 0.71
Analysts Strong Sell
Price Target $359.71

Company Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceu...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 354 6499
Address:
5 Park Plaza, Suite 1750, Irvine, United States
BouncePanda
BouncePanda Aug. 22 at 4:34 AM
$AEON AEON Biopharma is a clinical stage company with binary outcomes dependent on trial data extremely high risk with potential for large price swings on news
0 · Reply
VinWeezel
VinWeezel Aug. 15 at 6:34 PM
$AEON
2 · Reply
Fromtheotherside
Fromtheotherside Aug. 13 at 11:14 PM
$AEON Impact of ABP-450 Approval: If approved in the U.S./EU, ABP-450 could disrupt the $3B+ U.S. therapeutic botulinum toxin market (part of a $12.24B global market in 2024, projected to hit $30.59B by 2034). It offers a 20-40% cheaper alternative, increasing patient access and reducing costs for payers/providers. AEON could gain significant revenue, while Daewoong strengthens its global BoNT position. However, BOTOX (AbbVie) may face price pressure and market share loss, though its strong brand and non-interchangeability limit the impact. Biosimilars could grow the market by boosting volumes through competition.
0 · Reply
Fromtheotherside
Fromtheotherside Aug. 13 at 11:12 PM
$AEON 4. Production by Daewoong Pharmaceutical (FDA/Health Canada/EMA-Compliant): • Daewoong manufactures ABP-450 in a cGMP-compliant facility approved by FDA, Health Canada, and EMA. • Impact: Ensures reliable production, minimizing quality risks and supporting faster regulatory approval. About Daewoong Pharmaceutical: Daewoong Pharmaceutical, a leading South Korean pharma company founded in 1945, develops and manufactures drugs, including Nabota® (ABP-450), the first Asian botulinum toxin with FDA approval (via Evolus as Jeuveau). It operates globally, exporting to 100+ countries, with 2023 revenue of ~$890M and operating profit of ~$97M. Listed on Korea Stock Exchange (069620.KS), its market cap is ~$1.1-1.4B (1.5-1.9T KRW) as of August 2025. Daewoong invests heavily in R&D, including biosimilars and innovative drugs.
0 · Reply
Fromtheotherside
Fromtheotherside Aug. 13 at 11:11 PM
$AEON 2. ABP-450 Approved as Biosimilar in India, Mexico, Philippines: • ABP-450 (same as Jeuveau® for cosmetic use by Evolus) is approved as a BOTOX biosimilar in these countries, proving safety and efficacy. • Impact: Provides real-world data to support FDA/EMA submissions and boosts AEON’s credibility with investors/partners. 3. Exclusive Development/Distribution Rights in U.S., Canada, EU, UK, Other Territories: • AEON has exclusive rights from Daewoong to develop and sell ABP-450 for therapeutic uses in these regions. • Impact: Positions AEON to dominate the biosimilar market for botulinum toxin, assuming FDA/EMA approval, potentially capturing significant market share.
0 · Reply
Fromtheotherside
Fromtheotherside Aug. 13 at 11:10 PM
$AEON AEON Biopharma’s August 12, 2025 press release highlights progress in developing ABP-450 (prabotulinumtoxinA), a biosimilar to BOTOX®targeting a $3B+ U.S. therapeutic neurotoxin market. AEON is pursuing the FDA’s 351(k) biosimilar pathway for faster approval across all BOTOX therapeutic indications (e.g., migraine, spasticity) without separate trials. Recent Milestones Explained: 1. Progress in Comparative Analytical Assessment (CAA): • CAA involves lab tests to prove ABP-450’s structural and functional similarity to BOTOX (e.g., amino acid sequences, nerve-binding). AEON expects to complete primary structure analysis (by AEON) and select functional analyses (by Daewoong Pharmaceutical) in Q3 2025, building on prior toxicology and manufacturing data. The FDA has confirmed AEON’s alignment with CAA requirements. • Impact: Critical for FDA approval, enabling a Q4 2025 Type 2a meeting. Success could lead to faster market entry, offering a cheaper alternative.
0 · Reply
TheProbieAnalyst
TheProbieAnalyst Aug. 13 at 7:14 PM
$AEON Are the bulls winning or did a big short covered?
1 · Reply
Moonster25
Moonster25 Aug. 13 at 6:27 PM
$AEON Here you come out of the woodwork every so often with the shelf offering take, been awhile now
1 · Reply
ka1954
ka1954 Aug. 13 at 6:22 PM
$AEON yes they are not great, that's why they put out a shelf offering and they will dilute when they run this up 100%+ sometime in near future. many stocks have done this where i made a killing. LOL
0 · Reply
Mandi63
Mandi63 Aug. 13 at 9:57 AM
$AEON Their finances are not great
1 · Reply
Latest News on AEON
AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 10 days ago

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

May 23, 2025, 4:05 PM EDT - 3 months ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

May 19, 2025, 4:05 PM EDT - 3 months ago

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 3 months ago

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Apr 25, 2025, 4:05 PM EDT - 4 months ago

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

Apr 21, 2025, 4:05 PM EDT - 4 months ago

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

AEON Biopharma Announces CEO Transition

Mar 27, 2025, 4:05 PM EDT - 5 months ago

AEON Biopharma Announces CEO Transition

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 4:05 PM EDT - 5 months ago

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

Mar 4, 2025, 8:00 AM EST - 6 months ago

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

AEON Biopharma, Inc. Announces Reverse Stock Split

Feb 24, 2025, 2:00 PM EST - 6 months ago

AEON Biopharma, Inc. Announces Reverse Stock Split

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Feb 7, 2025, 4:05 PM EST - 7 months ago

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Jan 7, 2025, 9:37 AM EST - 8 months ago

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

Jan 3, 2025, 8:02 PM EST - 8 months ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:05 PM EST - 10 months ago

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 19, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

May 29, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

AEON Biopharma Reports First Quarter 2024 Financial Results

May 14, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports First Quarter 2024 Financial Results

AEON Biopharma Provides Update on Development Pipeline

May 9, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Provides Update on Development Pipeline

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

May 3, 2024, 7:00 AM EDT - 1 year ago

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

Mar 30, 2024, 10:53 PM EDT - 1 year ago

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 4:15 PM EDT - 1 year ago

AEON Biopharma Announces Redemption of Public Warrants

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 29, 2024, 3:45 PM EDT - 1 year ago

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Mar 19, 2024, 4:30 PM EDT - 1 year ago

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Mar 19, 2024, 4:29 PM EDT - 1 year ago

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Jan 18, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

Dec 12, 2023, 8:00 AM EST - 1 year ago

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

AEON Biopharma Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 8:15 AM EST - 1 year ago

AEON Biopharma Reports Third Quarter 2023 Financial Results

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

Oct 19, 2023, 4:05 PM EDT - 2 years ago

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

Aug 29, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Aug 24, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

Jul 24, 2023, 7:00 AM EDT - 2 years ago

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

BouncePanda
BouncePanda Aug. 22 at 4:34 AM
$AEON AEON Biopharma is a clinical stage company with binary outcomes dependent on trial data extremely high risk with potential for large price swings on news
0 · Reply
VinWeezel
VinWeezel Aug. 15 at 6:34 PM
$AEON
2 · Reply
Fromtheotherside
Fromtheotherside Aug. 13 at 11:14 PM
$AEON Impact of ABP-450 Approval: If approved in the U.S./EU, ABP-450 could disrupt the $3B+ U.S. therapeutic botulinum toxin market (part of a $12.24B global market in 2024, projected to hit $30.59B by 2034). It offers a 20-40% cheaper alternative, increasing patient access and reducing costs for payers/providers. AEON could gain significant revenue, while Daewoong strengthens its global BoNT position. However, BOTOX (AbbVie) may face price pressure and market share loss, though its strong brand and non-interchangeability limit the impact. Biosimilars could grow the market by boosting volumes through competition.
0 · Reply
Fromtheotherside
Fromtheotherside Aug. 13 at 11:12 PM
$AEON 4. Production by Daewoong Pharmaceutical (FDA/Health Canada/EMA-Compliant): • Daewoong manufactures ABP-450 in a cGMP-compliant facility approved by FDA, Health Canada, and EMA. • Impact: Ensures reliable production, minimizing quality risks and supporting faster regulatory approval. About Daewoong Pharmaceutical: Daewoong Pharmaceutical, a leading South Korean pharma company founded in 1945, develops and manufactures drugs, including Nabota® (ABP-450), the first Asian botulinum toxin with FDA approval (via Evolus as Jeuveau). It operates globally, exporting to 100+ countries, with 2023 revenue of ~$890M and operating profit of ~$97M. Listed on Korea Stock Exchange (069620.KS), its market cap is ~$1.1-1.4B (1.5-1.9T KRW) as of August 2025. Daewoong invests heavily in R&D, including biosimilars and innovative drugs.
0 · Reply
Fromtheotherside
Fromtheotherside Aug. 13 at 11:11 PM
$AEON 2. ABP-450 Approved as Biosimilar in India, Mexico, Philippines: • ABP-450 (same as Jeuveau® for cosmetic use by Evolus) is approved as a BOTOX biosimilar in these countries, proving safety and efficacy. • Impact: Provides real-world data to support FDA/EMA submissions and boosts AEON’s credibility with investors/partners. 3. Exclusive Development/Distribution Rights in U.S., Canada, EU, UK, Other Territories: • AEON has exclusive rights from Daewoong to develop and sell ABP-450 for therapeutic uses in these regions. • Impact: Positions AEON to dominate the biosimilar market for botulinum toxin, assuming FDA/EMA approval, potentially capturing significant market share.
0 · Reply
Fromtheotherside
Fromtheotherside Aug. 13 at 11:10 PM
$AEON AEON Biopharma’s August 12, 2025 press release highlights progress in developing ABP-450 (prabotulinumtoxinA), a biosimilar to BOTOX®targeting a $3B+ U.S. therapeutic neurotoxin market. AEON is pursuing the FDA’s 351(k) biosimilar pathway for faster approval across all BOTOX therapeutic indications (e.g., migraine, spasticity) without separate trials. Recent Milestones Explained: 1. Progress in Comparative Analytical Assessment (CAA): • CAA involves lab tests to prove ABP-450’s structural and functional similarity to BOTOX (e.g., amino acid sequences, nerve-binding). AEON expects to complete primary structure analysis (by AEON) and select functional analyses (by Daewoong Pharmaceutical) in Q3 2025, building on prior toxicology and manufacturing data. The FDA has confirmed AEON’s alignment with CAA requirements. • Impact: Critical for FDA approval, enabling a Q4 2025 Type 2a meeting. Success could lead to faster market entry, offering a cheaper alternative.
0 · Reply
TheProbieAnalyst
TheProbieAnalyst Aug. 13 at 7:14 PM
$AEON Are the bulls winning or did a big short covered?
1 · Reply
Moonster25
Moonster25 Aug. 13 at 6:27 PM
$AEON Here you come out of the woodwork every so often with the shelf offering take, been awhile now
1 · Reply
ka1954
ka1954 Aug. 13 at 6:22 PM
$AEON yes they are not great, that's why they put out a shelf offering and they will dilute when they run this up 100%+ sometime in near future. many stocks have done this where i made a killing. LOL
0 · Reply
Mandi63
Mandi63 Aug. 13 at 9:57 AM
$AEON Their finances are not great
1 · Reply
kwongaram
kwongaram Aug. 12 at 11:52 PM
$AEON Q2 Corporate Update Clinical and Regulatory Progress Summary • ABP-450 Development Status: Primary structural and functional analysis of the Botox® biosimilar (ABP-450) is expected to be completed by Q3 2025. • Regulatory Process: A Type 2a meeting with the FDA is planned for Q4 2025 to discuss future development steps, approval strategy, and regulatory requirements. • Approval Goal: The company aims to launch the product in the US market by demonstrating equivalent efficacy across all approved Botox® indications through the FDA 351(k) pathway. • Preclinical Data: Toxicology, manufacturing, and other supporting data have already been generated by the company and its licensing partner, Daewoong Pharmaceutical.
0 · Reply
G_33
G_33 Aug. 11 at 10:47 PM
$AEON Isn’t the fda news supposed be announced in August?
1 · Reply
cranberry1
cranberry1 Aug. 8 at 9:11 PM
$AEON going back to .40
0 · Reply
Moonster25
Moonster25 Aug. 8 at 7:16 PM
$AEON Just gets worse and worse
0 · Reply
Mandi63
Mandi63 Aug. 7 at 11:38 AM
$AEON Their a European partner EOLS . took a 50% drop after earnings . Thinking of buying some will not ad any AEON ….lack of management updates.
0 · Reply
VinWeezel
VinWeezel Aug. 6 at 4:10 PM
$AEON
0 · Reply
msp3501
msp3501 Aug. 5 at 3:16 PM
$AEON
0 · Reply
Drugtrade
Drugtrade Aug. 4 at 7:00 PM
$AEON magic 8 ball says $10 on september 10th at 8:54 am
1 · Reply
kwongaram
kwongaram Aug. 3 at 8:22 AM
$AEON You should check for company updates during this earnings release. The schedule for this FDA meeting will be announced.
0 · Reply
ka1954
ka1954 Aug. 1 at 3:07 PM
$AEON u guys know that just because markets are going down, u dont have to sell ur stock, right? LOL
1 · Reply
kwongaram
kwongaram Aug. 1 at 2:54 PM
$AEON Following this meeting, the company will likely seek funding to prepare a BLA application for commercialization. Official information indicates that the funding will occur in 2026 or after the development path is finalized, implying that the company intends to secure funding after the company's valuation increases as a result of this FDA meeting. The meeting is most likely to take place between October and December 2025, effectively solidifying the schedule.
0 · Reply
kwongaram
kwongaram Aug. 1 at 2:46 PM
$AEON After announcing the FDA meeting schedule, wait. If contact is made this month, an announcement will be made within this week or next. Specifically, the nonclinical data from the analytical study will be explained. The bottom line is that the FDA meeting will likely collapse in August as well.
0 · Reply